$6.01
3.84%
Nasdaq, Apr 21, 07:49 pm CET
ISIN
US1266381052
Symbol
CVRX

CVRx Inc Stock price

$6.25
-5.50 46.81% 1M
-1.85 22.84% 6M
-6.42 50.67% YTD
-9.46 60.22% 1Y
+1.55 32.98% 3Y
-21.75 77.68% 5Y
-21.75 77.68% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.10 1.63%
ISIN
US1266381052
Symbol
CVRX
Sector

Key metrics

Market capitalization $162.73m
Enterprise Value $107.23m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.09
P/S ratio (TTM) P/S ratio 3.17
P/B ratio (TTM) P/B ratio 2.23
Revenue growth (TTM) Revenue growth 30.53%
Revenue (TTM) Revenue $51.29m
EBIT (operating result TTM) EBIT $-59.49m
Free Cash Flow (TTM) Free Cash Flow $-40.51m
Cash position $105.93m
EPS (TTM) EPS $-2.70
P/E forward negative
P/S forward 2.65
EV/Sales forward 1.75
Short interest 12.97%
Show more

Is CVRx Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

CVRx Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a CVRx Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a CVRx Inc forecast:

Buy
86%
Hold
14%

Financial data from CVRx Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
51 51
31% 31%
100%
- Direct Costs 8.95 8.95
32% 32%
17%
42 42
30% 30%
83%
- Selling and Administrative Expenses 90 90
42% 42%
176%
- Research and Development Expense 11 11
4% 4%
22%
-59 -59
38% 38%
-115%
- Depreciation and Amortization 0.62 0.62
19% 19%
1%
EBIT (Operating Income) EBIT -59 -59
38% 38%
-116%
Net Profit -60 -60
46% 46%
-117%

In millions USD.

Don't miss a Thing! We will send you all news about CVRx Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CVRx Inc Stock News

Positive
Seeking Alpha
12 days ago
CVRx Inc. stock has recently dropped 40%, presenting a buying opportunity as the long-term growth potential remains intact. Barostim has strong clinical results and significant market potential, with a $2.2 billion TAM. Average selling prices can potentially improve as the market recognizes Barostim's effectiveness.
Neutral
GlobeNewsWire
14 days ago
First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024 First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024
Neutral
GlobeNewsWire
2 months ago
New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstr...
More CVRx Inc News

Company Profile

CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. It has developed the second generation Barostim neo, an implantable system designed to treat heart failure and hypertension. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2000 and is headquartered in Minneapolis, MN.

Head office United States
CEO Kevin Hykes
Employees 206
Founded 2001
Website www.cvrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today